GlassScriptPhysician profile
Candi C Overholt
NPI 1760686711
$16,457.99
in general payments reported to CMS, 2019-2025
66 companies · $2,324 in 2025
The $2,324 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $2,524 · 2021: $2,604 · 2022: $2,416 · 2023: $2,294 · 2024: $2,281 · 2025: $2,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,899.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,823.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,731.49 | 2019-2025 | |
| Lilly USA, LLC | $1,346.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,193.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Benlysta |
| Amgen INC. | $1,080.44 | 2019-2025 | Otezla, Enbrel, Repatha |
| Astrazeneca Pharmaceuticals LP | $895.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $694.96 | 2019-2025 | Trintellix |
| Pfizer INC. | $563.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.60 | 2019-2024 | Jardiance |
| Allergan, INC. | $468.49 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.16 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $426.85 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.55 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $320.44 | 2021-2025 | |
| Esperion Therapeutics, INC. | $319.69 | 2020-2025 | Nexletol |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candi Overholt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.